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sPIF promotes myoblast differentiation and
utrophin expression while inhibiting
fibrosis in Duchenne muscular dystrophy
via the H19/miR-675/let-7 and miR-21
pathways
Daria Morgoulis1, Peter Berenstein1, Simona Cazacu2, Gila Kazimirsky1, Amir Dori3, Eytan R. Barnea4 and Chaya Brodie1,2
Abstract
Duchenne muscular dystrophy (DMD) is a progressive, lethal, X-linked disease of skeletal and cardiac muscles caused
by mutations in the dystrophin gene. Loss of dystrophin leads to muscle fiber damage and impairment of satellite cell
asymmetric division, which are essential for muscle regeneration. These processes ultimately result in muscle wasting
and the replacement of the degenerating muscles by fibrogenic cells, a process that leads to the generation of fibrotic
tissues. Preimplantation factor (PIF) is an evolutionary conserved 15-amino acid peptide secreted by viable mammalian
embryos. Synthetic PIF (sPIF) reproduces the protective/regenerative effects of the endogenous peptide in immune
disorders and transplantation models. In this study, we demonstrated that sPIF treatment promoted mouse and
human myoblast differentiation and inhibited the expression of collagen 1A1, collagen 1A2, and TGF-β in DMD
patient-derived myoblasts. Additionally, sPIF increased the expression of utrophin, a homolog of dystrophin protein.
sPIF effects were mediated via the upregulation of lncRNA H19 and miR-675 and downregulation of let-7. sPIF also
inhibited the expression of miR-21, a major fibrosis regulator. The administration of sPIF in mdx mice significantly
decreased serum creatine kinase and collagen I and collagen IV expression in the diaphragm, whereas it increased
utrophin expression in the diaphragm, heart and quadriceps muscles. In conclusion, sPIF promoted the differentiation
of DMD myoblasts, increased utrophin expression via the H19/miRNA-675/let-7 pathway, and reduced muscle fibrosis
possibly via the upregulation of miR-675 and inhibition of miR-21 expression. These findings strongly support pursuing
sPIF as a potential therapeutic agent for DMD. Moreover, the completion of an sPIF phase I safety trial will further
promote the use of sPIF for the treatment of muscular dystrophies.
Introduction
Duchenne muscular dystrophy (DMD) is a recessive,
fatal, X-linked disease and the most common form of
muscular dystrophy1. DMD is caused by mutations in the
dystrophin gene that can be either spontaneous or inher-
ited2,3. The dystrophin protein plays a critical role in the
maintenance, integrity, and normal functions of muscle
cells, and its loss leads to progressive muscle degenera-
tion4,5. Under normal conditions, muscle damage activates
quiescent muscle stem cells (satellite cells), which even-
tually differentiate into mature muscle cells and contribute
to tissue regeneration6. Recent studies indicate that
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dystrophin is also essential for the asymmetric division of
satellite cells, and the lack of functional protein interferes
with the regenerative capacity of these cells7. Thus, muscle
regeneration is impaired in DMD, resulting in the repla-
cement of degenerating muscle fibers by fibrotic and fat
tissues1,8.
Various therapeutic approaches have been explored for
treating DMD, including promotion of muscle regenera-
tion9, anti-inflammatory and anti-fibrotic agents2,10,11,
and exon-skipping with antisense oligonucleotides12,13.
Despite these efforts, there is currently no cure for DMD,
and treatments focus mainly on relieving the symptoms
and minimizing complications14.
Preimplantation factor (PIF) is a 15-amino acid peptide
secreted by viable embryos, which through autotrophic
action promotes development and protects against
embryo demise due to adverse environments15–18. PIF
promotes implantation and placental engraftment, and
reduces spontaneous and Lipopolysaccharide (LPS)-
induced fetal demise in an immune intact murine
model19–21. The synthetic PIF analog (sPIF) replicates
the native peptide actions and has comprehensive
immune protective and regenerative properties22–24. sPIF
targets innate immunity (macrophages/neutrophils)
and affects activated T-cell proliferation and mixed
lymphocyte reaction22 as well as decreased NK cytotoxi-
city25. Through an integrated local and systemic
effect, sPIF protects against juvenile diabetes26, cardio-
vascular inflammation27, radiation-induced injury28, neu-
roinflammation, and neurotrauma in various animal
models29–32. In addition, sPIF promotes ovarian allo-
transplantation in transplantation models in primates and
semi and allogeneic bone marrow transplantation33,34.
Recently, sPIF was the subject of a successful University-
initiated FDA Fast-Track-awarded Phase I clinical trial for
autoimmune hepatitis and obtained Orphan Drug Des-
ignation (www.clinicaltrials.gov, NCT 02239562).
In this study, we demonstrated that sPIF increased
muscle cell differentiation and utrophin level while inhi-
biting fibrogenic gene expression and identified the H19/
miR-675/let-7 and miR-21 pathways as mediators of sPIF
effects. Moreover, sPIF administration to mdx mice
decreased creatine kinase (CK) levels and tissue fibrosis
and increased the expression of utrophin, thus inducing a
change in biomarkers that suggests a therapeutic effect.
Results
sPIF increases the differentiation of human and mouse
myoblasts and decreases collagen and TGF-β expression
To study the effects of sPIF, we employed two in vitro
systems: mouse C2C12 cells and human myoblasts
derived from healthy donors and DMD patients. We first
examined the effects of sPIF on myoblast differentiation
by analyzing the expression of the myogenic factors,
MyoD and myogenin, which are required for the proper
differentiation of myogenic cells during the differentiation
and repair of myosin heavy chain (MyHC), which is
expressed in differentiated muscle cells. The fusion of
myoblasts into differentiated myotubes was also deter-
mined. Myoblasts were cultured in a medium containing
2% horse serum for 10 days to allow cell differentiation.
sPIF was added to the cells at the beginning of the culture
and every 2 days thereafter. Treatment of C2C12 cells
with sPIF increased the expression of MyoD, myogenin,
and MyHC (Fig. 1a) as well as cell fusion (Fig. 1b).
Similarly, sPIF increased the expression of MyHC and
troponin in human myoblasts derived from both healthy
donors and DMD patients (Fig. 1c). The internalization of
sPIF in muscle cells was followed using Fluorescein iso-
thiocyanate (FITC)-labeled sPIF and confocal microscopy.
As presented in Fig. 1d, sPIF accumulated in the cells
within 72 min of incubation and was localized in the
cytoplasm.
Muscles from DMD patients and mdx mice exhibit
increased tissue fibrosis that is due, partly, to the
increased transdifferentiation of myoblasts into myofi-
broblasts. Indeed, recent studies from our laboratory
demonstrated that muscle cells from DMD patients
express increased fibrogenic phenotypes compared to
control cells35. In contrast to its promoting effect on the
myogenic differentiation of DMD myoblasts, sPIF inhib-
ited the fibrogenic differentiation of these cells and
decreased the expression of collagen 1A1 and 1A2 and
that of TGF-β (Fig. 1e), which plays a major role in
fibrogenesis. Similar results were obtained in two addi-
tional DMD myoblasts (data not shown). Another
important factor that plays a central role in tissue fibrosis
is miR-2136. We found that human muscle cells from
DMD patients expressed higher levels of miR-21 com-
pared with control muscle cells (Fig. 1f). Treatment with
sPIF (300 nM) significantly decreased the expression of
miR-21 in DMD muscle cells (Fig. 1g).
Silencing of miR-21 in DMD cells inhibited the
expression of collagens 1A1 and 1A2 (Fig. 1h), and the
treatment with sPIF induced an additional modest
decrease. These effects were repeated in two additional
DMD muscle cells. The results suggest that the down-
regulation of miR-21 expression by sPIF plays a role in its
inhibitory effects on the fibrogenic differentiation of these
cells and that additional pathways may be also involved.
sPIF increases myoblast differentiation via the induction of
lncRNA H19 and miR-675
To further analyze the mechanisms involved in the
effects of sPIF on muscle differentiation, we focused on
the H19/miR-675 pathway. Long non-coding RNA
(lncRNA) H19 plays an essential role in muscle differ-
entiation and regeneration, and its biological functions are
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mediated by miR-675–3p and miR-675–5p, which are
encoded by exon 1 of H1937. Myoblasts derived from
DMD patients expressed significantly reduced levels of
H19 and miR-675 compared to myoblasts derived from
healthy donors (Fig. 2a). The treatment of DMD myo-
blasts with sPIF significantly upregulated the expression
of both H19 (Fig. 2b) and miR-675 (Fig. 2c) in these cells,
and these effects were observed in two additional DMD
muscle cells (sPIF 100 nM; DMD-Mus2–H19: 398.4 ±
4.2%; miR-675: 428.96 ± 5.11%; DMD-Mus3–H19: 312 ±
39.6; miR-675: 287 ± 23.1% compared to 100% in control
untreated cells).
To demonstrate that the induction of miR-675 played a
role in sPIF-induced myoblast differentiation we per-
formed two experiments. First, we transfected DMD
myoblasts with an siRNA duplex that targets H19 and
showed that the silencing of H19 decreased miR-675
expression in myoblasts (Fig. 2d) and their differentiation
by sPIF (Fig. 2e). We next transfected the DMD myoblasts
with miR-675–3p and miR-675–5p mimics and found
that the expression of MyHC and troponin was sig-
nificantly increased after 5 days of treatment (Fig. 2f). We
also examined the effects of sPIF on the differentiation of
myoblasts transfected with miR-675 antagomiRs and
found that its effects were markedly abrogated, whereas,
no significant decrease in the effects of sPIF was observed
in myoblasts transfected with a control antagomiR
(Fig. 2g). These results indicate that the induction of H19
and the subsequent upregulation of miR-675 mediated, at
least partly, some of the increased differentiation of the
Fig. 1 sPIF increases the differentiation of mouse and human myoblasts. C2C12 cells and human myoblasts were cultured in 2% HS and treated
with sPIF (300ng/ml) for 10 days. The expression of the different myogenic proteins was determined using western blot analysis (*P < 0.001, control vs
sPIF-treated cells; **P < 0.01, MyHC and troponin expression in control vs DMD muscle cells) (a). C2C12 cells were cultured in 2% HS and after 10 days
stained with DAPI and anti-myosin heavy chain (MyHC) antibody (FITC). Cell fusion was analyzed using confocal microscopy (b). Human myoblasts
derived from three DMD patients (DMD-mus) and two healthy donors (H-mus) were treated with sPIF (300ng/ml) and analyzed for the expression of
MyHC and troponin following 10 days in fusion medium using RT-PCR (P < 0.001) (c). The internalization of sPIF-FITC into C2C12 cells was analyzed by
live cell imaging using confocal microscopy. The fluorescence of the cells at the initial stage of the experiment and after 72 min is presented (d). The
effects of sPIF (300 nM, 2 days) on the expression of Col 1A1, Col 1A2, and TGF-β in DMD myoblasts were determined using RT-PCR (P < 0.001) (e). The
expression of miR-21 was determined in muscle cells obtained from healthy donors and DMD patients (f) and in DMD muscle cells treated with sPIF
(*P < 0.001) (g). The effects of miR-21 antagomiR on the expression of Col 1A1 and Col 1A2 in control and sPIF-treated DMD muscle cells were
determined after 3 days of treatment (*P < 0.001 for sPIF and miR-21 antagomiR vs control; **P < 0.01 for sPIF+miR-21 antagomiR vs sPIF alone)
(h). The results are representative of three similar experiments and are presented as the means ± SE. DAPI, 4′,6-diamidino-2-phenylindole; DMD,
Duchenne muscular dystrophy; HS, horse serum; RT-PCR, real-time polymerase chain reaction; sPIF, synthetic PIF analog
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human myoblasts by sPIF. These results exhibited similar
patterns in additional DMD muscle cells (data not
shown).
sPIF increases utrophin expression via the H19/miR-675/
let-7 pathway
Utrophin is a functional and structural autosomal
paralog of dystrophin. These proteins share binding
partners, and upregulating utrophin expression is con-
sidered a potential therapeutic approach in DMD. In
addition to its effect on myoblast differentiation, sPIF
treatment also increased the expression of utrophin in
C2C12 (Fig. 3a) and human muscle cells (Fig. 3a, b). This
effect of utrophin was observed in additional muscle
cultures from healthy and DMD donors (sPIF treated—H-
Mus2: 452.3 ± 40.2%; DMD-Mus2: 532.8 ± 48.2%; DMD-
Mus3: 387.1 ± 30.6% compared to 100% in control
untreated cells). The induction of utrophin in human
myoblasts was partly dependent on the increased
expression of H19 since silencing of this lncRNA abro-
gated the upregulation of utrophin expression (Fig. 3c).
H19 acts as a sponge of let-738, which targets the 3’-UTR
of utrophin39,40, suggesting that the upregulation of H19
may interfere with the ability of let-7 to target utrophin.
We, therefore, examined the effects of let-7 silencing on
utrophin expression in DMD myoblasts and found an
increased utrophin expression in the let-7-silenced myo-
blasts (Fig. 3d). Since sPIF was recently reported to
downregulate let-7 expression in neural and lymphoid
cells by decreasing its biogenesis, we examined the effects
of sPIF on let-7 expression also in muscle cells30. Treat-
ment of human myoblasts with sPIF decreased the
expression of let-7 (Fig. 3e), and the overexpression of let-
7 abrogated the upregulation of utrophin by sPIF (Fig. 3f).
These results suggest that sPIF may increase utrophin
expression by decreasing let-7 expression and by inhibit-
ing the ability of let-7 to target utrophin via the upregu-
lation of H19.
Fig. 2 sPIF increases the differentiation of DMD myoblasts via the upregulation of the H19/miR-675 pathway. The expression of H19 and
miR-675 was analyzed in cultured muscle cells derived from healthy donors and DMD patients using RT-PCR (*P < 0.001) (a). sPIF induced the
upregulation of both H19 (b) and miR-675–3p and -5p expression (c) as determined by RT-PCR (*P < 0.001). DMD myoblasts were transfected with a
control or H19 siRNA. The expression of miR-675 (d) and the induction of MyHC by sPIF were determined by RT-PCR (*P < 0.001 for untreated vs/sPIF-
treated cells and control vs H19 siRNA cells treated with sPIF) (e). DMD myoblasts were transfected with miR-675–3p or miR-675–5p mimics, and the
expression of MyHC and troponin was determined 7 days later (*P < 0.001 for MyHC and troponin expression of con siRNA vs miR-675-overexpressing
cells) (f). The effect of sPIF on MyHC expression was determined in DMD myoblasts transfected with a control or miR-675 antagomiRs (*P < 0.001 for
sPIF-treated cells expressing miR-675 antagomiRs vs cells expressing a control antagomiR) (g). The results are representative of at least three similar
experiments and presented as the means ± SE. DMD, Duchenne muscular dystrophy; MyHC, myosin heavy chain; RT-PCR, real-time polymerase chain
reaction; sPIF, synthetic PIF analog
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sPIF decreases CK levels and muscle tissue fibrosis in mdx
mice
We further studied the therapeutic effects of sPIF on
mdx mice that represent a pre-clinical model of DMD and
have a premature stop codon mutation on exon 23 of the
dystrophin gene, which results in a lack of the mature
protein. sPIF (0.75 mg/kg) was administered twice a day
subcutaneously (SC) or SC and intramuscularly to the
quadriceps muscles (QC) for 2 weeks. Mice were sacri-
ficed at the end of the treatment and 2 weeks thereafter.
We found that sPIF treatment significantly decreased
serum CK levels when examined 4 weeks post adminis-
tration (Fig. 4a), suggesting that sPIF exerted a therapeutic
impact in this disease model.
Muscle fibrosis is one of the hallmark processes in
DMD, resulting from muscle degeneration and correlat-
ing with patient functional deterioration41,42. In mdx
mice, fibrosis is mainly observed in the diaphragm and
heart43,44. We therefore analyzed the effects of sPIF on
fibrosis in these tissues. Mice treated with sPIF for
2 weeks were sacrificed 2 weeks later, and the diaphragm
tissues were analyzed for collagen I and IV expression
using immunofluorescence staining. The expression of
collagen I and IV in the diaphragm of sPIF-treated mice
was significantly lower compared with that in the tissues
of control mice (Fig. 4b). In contrast, sPIF did not induce
a significant decrease in collagen I or IV expression in
cardiac tissues (data not shown).
Fig. 3 sPIF upregulates utrophin expression via the H19/Let-7 pathway. C2C12 and human myoblasts were treated with sPIF for 10 days and
utrophin expression was determined by western blot analysis (a). Utrophin expression was also analyzed in sPIF-treated DMD myoblasts as
determined by RT-PCR (b). DMD myoblasts were silenced for H19, and the effects of sPIF on utrophin expression were determined following 5 days
of treatment (c). DMD myoblasts were treated with a control or let-7 antagomiR, and utrophin expression was analyzed 3days later using RT-PCR and
western blot analysis (d). The expression of let-7 was determined in DMD myoblasts following sPIF treatment for 3 days by RT-PCR (e). DMD
myoblasts were transfected with a control or let-7 mimic and then treated with sPIF for 5 days. Utrophin expression was determined by RT-PCR
(f). The results are representative of at least three similar experiments and presented as the means ± SE. *P < 0.001. DMD, Duchenne muscular
dystrophy; RT-PCR, real-time polymerase chain reaction; sPIF, synthetic PIF analog
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sPIF increases utrophin expression in muscle tissues
Recent studies have reported an inverse correlation
between fibrosis and utrophin expression in both patient
biopsies and mdx mice44. We found that sPIF increased
utrophin in cultured cells and therefore examined the
effects of sPIF also on utrophin expression in mdx muscle.
sPIF treatment significantly increased utrophin expression
in the QC (Fig. 5a, b), diaphragm (Fig. 5c), and cardiac
(Fig. 5d) muscle tissues of mdx mice.
Discussion
DMD is an X-linked muscle degenerative disease that
currently has no cure. New therapeutic strategies being
pursued for the treatment of this disease include ster-
oids45, cell-based therapies46, and increasing functional
dystrophin expression47.
In this study, we focused on sPIF as a potential ther-
apeutic agent for the treatment of DMD and on analyzing
the molecular mechanism underlying its effects using
both mouse and human in vitro models and mdx mice.
The immune regulatory and regenerative actions of sPIF
have been recently reported22,48. sPIF promotes embryo
differentiation to the blastocyst stage through a targeted
action and protects against oxidative stress and protein
misfolding15–18. The trophic and protective actions of
sPIF were also confirmed by demonstrating its effects on
reducing inflammation and promoting neural repair and
re-myelination in the spinal cord and brain29,32,48. Simi-
larly, in a newborn hypoxic ischemic model, sPIF treat-
ment was able to restore the size of the injured cortex30,31.
sPIF mostly regulates activated immune response without
leading to immune suppression and preserves anti-
pathogen action22. Thus, sPIF may limit damage and
inflammation and promote tissue regeneration28,30,34.
sPIF increased the differentiation of both C2C12 cells
and human myoblasts derived from healthy donors and
DMD patients, whereas it inhibited the fibrogenic phe-
notypes of DMD myoblasts. Muscle cells derived from
DMD patients exhibited decreased expression of lncRNA
H19 and miR-675 compared to healthy donor-derived
Fig. 4 sPIF decreased CK levels and tissue fibrosis in mdx mice. Mice (6 weeks; n= 8 per group) were injected with PBS (controls) or sPIF (0.75
mg/kg twice daily for 2 weeks) either SC or once SC and once to the QC muscle. CK levels were analyzed at the end of the treatment and following
additional 2 weeks (*P < 0.01) (a). Diaphragm muscles from the treated mice were removed and stained for anti-collagen I and collagen IV (b). The
levels of collagen I and collagen IV were analyzed for fluorescence signal intensity using CellProfiler software tool and presented as a graph (*P <
0.01). CK, creatine kinase; PBS, phosphate-buffered saline; QC, quadriceps; SC, subcutaneously; sPIF, synthetic PIF analog
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cells. H19 has been identified as an important lncRNA in
the function of skeletal muscle differentiation by
increasing the expression of miR-675, which in turn
inhibits the TGF-β pathway37. sPIF increased the
expression of H19, miR-675–3p, and miR-675–5p in
DMD myoblasts and the differentiation of these cells in an
miR-675-dependent manner. This is the first study that
demonstrates the effect of sPIF on DMD myoblast dif-
ferentiation and identifies the H19/miR-675 pathway as a
mediator of this effect.
In addition to the in vitro effects, sPIF also exerted a
therapeutic impact in mdx mice, which are used as a DMD
animal model49. Treatment with sPIF significantly decreased
the serum CK levels in the treated mice, which reflects the
decreased muscle degeneration and tissue damage.
Tissue fibrosis is one of the characteristic pathological
hallmarks of DMD and represents a secondary process to
the degeneration of muscle tissues41,50. Muscle fibrosis is
directly correlated with disease progression and poor
prognosis51. Tissue fibroblasts are considered the main
mediators of this process; however, recent studies have
reported that DMD myoblasts can also contribute to
muscle fibrogenesis50. We found that sPIF decreased the
fibrosis levels in the diaphragm of the mdx mice as indi-
cated by the decreased immunofluorescence staining of
collagen I.
sPIF inhibited the expression of the fibrogenic pheno-
type and TGF-β expression in DMD muscle cells. sPIF
also decreased the expression of miR-21, which was
higher in DMD muscle cells compared with control
myoblasts. miR-21 plays a major role in the fibrosis of
various tissues, including liver, renal, and cardiac muscle,
and in age-associated muscular dystrophy36,52–54. Thus,
the upregulation of miR-675 and the decreased miR-21
expression, which target the TGF-β pathway and collagen
expression, respectively, may mediate the inhibitory effect
of sPIF on tissue fibrosis.
Similar to its effects in cultured myoblasts, sPIF also
induced the expression of utrophin in the QC, diaphragm,
and cardiac tissues of mdx mice. Utrophin is a homolog of
dystrophin protein, which is mainly expressed during the
embryonic development of skeletal muscles and replaced
by dystrophin postnatally55. Upregulation of utrophin
levels is considered a potential therapeutic approach for
Fig. 5 sPIF increases the expression of utrophin in mdx mice. Mice were injected with PBS or sPIF as described in Fig. 4. Following 2 additional
weeks, the quadriceps (a), diaphragm (c), and cardiac (d) muscle tissues were immunostained with an anti-utrophin antibody (red) and the sections
visualized by confocal microscopy. The levels of utrophin were analyzed for fluorescence signal intensity using CellProfiler software tool and
presented as a graph. Tissue sections of the quadriceps muscle were also analyzed for the expression of utrophin using RT-PCR (b). The results are
representative of at least three similar experiments and presented as the means ± SE (*P < 0.001). PBS, phosphate-buffered saline; RT-PCR, real-time
polymerase chain reaction; sPIF, synthetic PIF analog
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the treatment of DMD since this protein can substitute
for some of the dystrophin functions in the muscles of
DMD patients56. Recent studies have reported that utro-
phin is directly targeted by let-7 via binding to its 3‘-UTR.
Our results demonstrate that sPIF downregulates let-7
expression thereby providing a potential mechanism for
the upregulation of utrophin by sPIF. Indeed, sPIF was
reported to downregulate let-7 expression also in neuro-
nal and lymphoid cells by inhibiting its biogenesis30.
Another mechanism by which sPIF increases utrophin
levels may be via the upregulation of H19 expression. H19
acts as a sponge of let-7 and therefore can interfere with
the targeting of utrophin by let-7. Interestingly, the
expression of utrophin has been reported to be inversely
correlated with the level of fibrosis in DMD muscle44,
which can further contribute to the upregulation of
utrophin secondary to the decreased fibrosis induced by
sPIF.
The results of this study demonstrate that sPIF pro-
motes muscle differentiation in vitro and exerts a ther-
apeutic impact in mdx mice by decreasing the levels of
fibrosis and inducing utrophin expression. The effects of
sPIF were at least partially mediated via the upregulation
of the H19/miR-675 pathway and downregulation of let-7
and miR-21 (Fig. 6). Additional factors, including
inflammatory cytokines and TGF-β, are also likely to play
a role in sPIF effects and are currently being explored.
Phase I clinical trial has been now completed for sPIF in
autoimmune hepatitis. Based on this and our current
results, we propose that sPIF represents a potential ther-
apeutic agent for the treatment of DMD.
Materials and methods
Materials
The following antibodies were employed: myosin heavy
chain (sc-376157), myoD (sc-760), Pax-7 (sc-81975),
β-actin HRP-conjugated antibody (sc-47778HRP), and
GAPDH (sc-26778) from Santa Cruz Biotechnology
(Dallas, TX, USA); collagen I (Ab21286) and collagen IV
(ab19808) from Abcam, Cambridge, UK; utrophin
(NCL-DRP2) from Leica Biosystems Inc. (Buffalo
Grove, IL, USA); donkey anti-rabbit Cy-3-conjugated
antibody (#711–166–152) and donkey anti-mouse Cy-3-
conjugated antibody (#715–165–151) from Jackson
ImmunoResearch Laboratories Inc. (West Grove,
PA, USA); goat anti-mouse Alexa488-conjugated anti-
body (#A-11029) from Molecular Probes Inc., Carlsbad,
CA, USA; and 4′,6-diamidino-2-phenylindole (DAPI)
(D1306) from ThermoFischer Scientific (Oregon City,
OR, USA).
Cultures of human myoblasts and C2C12 cells
Myoblasts from healthy male donors (H-Mus) and
DMD patients (DMD-Mus) were obtained from ScienCell
(Carlsbad, CA, USA) and from Creative Bioarray and DV
Biologics (Costa Mesa, CA, USA), as previously
reported35.
C2C12 myoblasts were maintained at subconfluent
densities in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum (Invitrogen,
Paisley, UK). Myogenic differentiation was induced by
changing subconfluent cells to DMEM containing 2%
heat-inactivated horse serum as recently reported35.
Transfection of miRNA mimics, antagomiRs, and shRNAs
RNA duplexes corresponding to miR-675 and miR-21
mimics were obtained from Sigma (St. Louis, MO, USA).
Transfection of the cells with the miRNA duplexes was
carried out with siIMPORTER (Millipore) according to
the manufacturer’s instructions and as previously repor-
ted57. H19 shRNA was obtained from Dharmacon,
and miR-675 and miR-21 antagomiRs were obtained from
SBI.
Western blot analysis
Cell lysates (30 μg protein) were analyzed for the
expression of specific markers as previously described35.
Fusion analysis
C2C12 cells were plated in DMEM supplemented with
10% fetal bovine serum in a 35-mm imaging dish with an
ibidi Polymer Coverslip Bottom at high density (80%) and
allowed to proliferate for 48h. The medium was then
replaced with a differentiation medium containing 2%
horse serum, and the cells were cultured for an additional
10 days. sPIF (300 nM) was added to the culture medium
at the beginning of the differentiation phase and every 48h
thereafter.
Fusion index was quantified as the ratio of DAPI-
stained nuclei in MyHC-positive multinucleated cells
with ≥ 3 nuclei to the total number of stained nuclei.
Analysis was performed using ImageJ software of 49 fields
Fig. 6 A diagram summarizing the various molecular and cellular
pathways associated with sPIF effects in DMD. The different
in vitro and in vivo effects of sPIF and its various pathways and
mediators are depicted in this diagram
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in each of the two independent culture dishes per group
as previously described35.
Real-time quantitative PCR analysis–
Total RNA was isolated using QIAzol reagent (Qiagen,
CA, USA) according to the manufacturer's protocol. Half
microgram of RNA was employed to synthesize cDNA by
Thermoscript (Invitrogen) with oligo dT primers. mRNAs
were analyzed by the TaqMan assay kits for troponin T
(Human TNNT3 Fast skeletal muscle); myosin heavy
chain type 2a fast–MyH2 (human: MyH2
Hs00952980_m1), and utrophin (human: Hs01125975_
m1; mouse: Mn01168866_m1) from ThermoFisher Sci-
entific. S12 mRNA was used as an internal control.
Expression of miR-21, miR-875, and H19 was determined
by the TaqMan stem-loop real-time polymerase chain
reaction method. Primers and probes for TaqMan miRNA
assay and the endogenous control RNU6B were pur-
chased from System Biosciences.
Animal studies
All animal experiments were performed in accordance
with the guidelines of the Israel Board for Animal
Experiments and in compliance with The Israel Animal
Welfare Act and Ethics Committee. The mdx mice (6-
week-old males) were housed in cages under conditions
of constant photoperiod (12/12h light/dark) with free
access to food and water. Mice were treated with sPIF,
0.75 mg/kg/10 μl, twice a week for 2 weeks either SC or
by a combination of SC and intramuscular injections
into the QC muscles. The control mice were injected
with saline. The diaphragm, heart, and QC muscles were
collected immediately after sPIF administration and for
two additional weeks thereafter and were processed for
histological and immunofluorescence analyses.
Preparation of sections and immunofluorescence
Muscle tissues from the control and treated mice were
collected and frozen in isopentane cooled with liquid
nitrogen. Cryosections were prepared, fixed, and blocked
with 0.2% (w/v) gelatin and 0.2% (v/v) Tween20 (Sigma
Aldrich; P1379) in phosphate-buffered saline and immu-
nostained with anti-utrophin antibody (1:50) alone or
double-immunostained with collagen type I (1:100) or
collagen type IV (1:50) antibodies. Cell nuclei were
stained with DAPI (1:1000). As secondary antibodies, goat
anti-mouse IgG antibodies with Alexa Fluor dye were
used for collagen type I detection and Cy3 anti-goat for
utrophin detection. Microscopic observations and image
acquisition were performed with Leica SP8 Confocal and
Zeiss Axioimager fluorescent microscopes and analyzed
using CellProfiler software as previously reported35.
Images from 8–12 different fields were acquired and
analyzed for each mice.
Statistical analysis
Quantitative measurements are presented as the mean
values ± SE and visualized in bar charts. Data were ana-
lyzed using ANOVA or Student's t test, with correction
for datasets with unequal variances.
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